Molecular evaluations of extended spectrum β-lactamase producing strains of Serratia isolated from blood samples of the patients in Namazi Hospital, Shiraz, Southern Iran
,
Abstract
Background and Objective: Nowadays, the presence of extended-spectrum β-lactamases (ESBLs) producing strains in Serratia genus causes the emergence of resistance to many antibiotics. So, the lack of proper diagnosis of ESBLs strains can lead to failure in the treatment. The objective of the present study was to investigate ESBLs production in Serratia strains isolated from the clinical blood samples in Shiraz, Iran.
Materials and Methods: In this study, 39 Serratia strains isolated from the patients referred to Namazi Hospital, during a 2 year period were tested. The antimicrobial resistance of the isolates to 21 antibiotics was evaluated using Kirby-Bauer disk diffusion method. Combination disk method was used to determine the ESBL phenotype among the isolates. PCR was performed to investigate the presence of ESBL genes of SHV, OXA and TEM types.
Results: The lowest antibiotic resistance rates belonged to meropenem (7.69%) and imipenem (5.12%). Overall, positive ESBL phenotype was identified in 69% (n = 27) of the isolates, 70.37% (n = 19) for S. marcescens and 29.62% (n = 8) for S. liquefaciens. Results obtained by PCR showed that only 20.51% carried OXA gene and 15.38% carried SHV-1 gene. TEM gene was detected in none of the isolates.
Conclusion: This study showed a high prevalence of the emerging ESBL producing strains among clinical isolates of Serratia that could lead to an increase in antibiotic resistance. However, ESBLs genes other than those tested here may be more responsible for the emergence of ESBL phenotype among Serratia clinical isolates in our region.
Karen B, George AJ, Antone AM. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33.
David LP, Robert AB. Extended-spectrum β-lactamases:a clinical update. Clin Microbiol Rev 2005; 18: 657-686.
Ranjbar R, Ghazi FM, Farshad S, Giammanco GM, Aleo A, Owlia P, et al. The occurrence of extended-spectrum β-lactamase producing Shigella spp. in Tehran, Iran.Iran J Microbiol 2013; 5: 108-12.
Ranjbar R,Giammanco GM, Aleo A, Plano MR, Naghoni A, Owlia P, et al. Characterization of the first extended-spectrum beta-lactamase-producing nontyphoidal Salmonella strains isolated in Tehran, Iran. Foodborne Pathog Dis 2010; 7: 91-5.
Karen B. New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32: 1085-1089.
Du Bois SK, Marriott MS, Amyes SG. TEM- and SHV- derived extended-spectrum beta-lactamases: relationship between selection, structure and function. J Antimicrob Chemother 1995; 35: 7-22.
George AJ. Extended-spectrum beta-lactamases Antimicrob Agents Chemother 1989; 33: 1131-1136.
Yu WL, Lin CW, Wang DY.Serratia marcescens bacteremia: clinical features and antimicrobial susceptibilities of isolates. J Microbiol Immunol Infect 1998; 31: 171-179.
National Committee for Clinical Laboratory Standards (NCCLS), Wayne (PA) (2005). Performance standards for antimicrobial susceptibility testing. Disk diffusion,15th Informational supplement. M100-S15.
Clinical and Laboratory Standards Institute (CLSI), Wayne (PA) (2009). Performance Standards for Antimicrobial Susceptibility Testing, 19th informational supplement. M100-S19.
Dong L, Min Y, Jianying H, Jing Z, Ruyin L, Xin G, et al. Antibiotic-resistance profile in environmental bacteria isolated from penicillin production wastewater treatment plant and the receiving river. Environ Microbiol 2009; 11: 1506-1517.
Hong F, Christina L, Barbro OL, Goran H, Emma L, Asa R, et al. Molecular epidemiological analysis of Escherichia coli isolates producing extended-spectrum beta-lactamases for identification of nosocomial outbreaks in Stockholm, Sweden. J Clin Microbiol 2004; 42: 5917-5920.
Marc O, Luc B, Paul HR. Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamases gene. Proc Natl Acad Sci USA 1987; 84: 7378-7382.
Patricia AB. Extended-spectrum β-lactamases in the 21 st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951.
Lii Tzu W, Mei Fen T, Hwa Jene W, Hui En C, Yin Ching C, Wen Liang Y. Survey of CTX-M-3 extended- spectrum β-lactamase (ESBL) among cefotaxime- resistant Serratia marcescens at a medical center in middle Taiwan. Diagn Microbiol Infect Dis 2004; 49:125-129.
Wen Liang Y, Lii Tzu W, Michael AP, Patricia LW, Ronald NJ. Confirmation of extended-spectrum β-lactamase-producing Serratia marcescens: preliminary report from Taiwan. Diagn Microbiol Infect Dis 2003;45: 221-224.
David LP, Wen Chien K, Anne Von G, Jose Maria C, Lutfiye M, Keith PK, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-2212.
David LP, Wen Chien K, Anne Von G, Sunita M, Jose Maria C, Herman G, et al. Antibiotic therapy for Klebsiella pneumonia bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004; 39: 31-37.
Mario T, Michela S, Enrico Maria T, Fiammetta L, Marianna R, Barbara F, et al. “Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy”. Antimicrob Agents Chemother 2008; 52: 3244-3252.
Marek G. Evolution and epidemiology of extended- spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001; 7: 597-608.
Elvira GG, Sandra IMI, Jorge MLD, Gloria M G. “Molecular characterization and antimicrobial susceptibility of extended-spectrum {beta}-lactamase- producing Enterobacteriaceae isolates at a tertiary-care center in Monterrey, Mexico”. J Med Microbiol 2011;60: 84-90.
Kuo Chen C, Yin Ching C, Lii Tzu W, Guan Cheng H, Wen Liang Y. “Clinical experiences of the infections caused by extended-spectrum β-lactamase-producing Serratia marcescens at a medical center in Taiwan”. Jpn J Infect Dis 2006; 59: 147-152.
| Files | ||
| Issue | Vol 5 No 4 (2013) | |
| Section | Articles | |
| Keywords | ||
| Extended-spectrum β-lactamases OXA SHV Serratia TEM | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
